<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01099202</url>
  </required_header>
  <id_info>
    <org_study_id>ID02-591</org_study_id>
    <nct_id>NCT01099202</nct_id>
  </id_info>
  <brief_title>Procrit Versus No Procrit in Acute Lymphocytic Leukemia, Lymphoblastic Lymphoma, or Burkitt's Undergoing Induction/Consolidation Chemotherapy</brief_title>
  <official_title>A Randomized Study of Procrit Versus No Procrit in Patients With Acute Lymphocytic Leukemia, Lymphoblastic Lymphoma, or Burkitt's Undergoing Induction/Consolidation Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to learn if Procrit (epoetin alfa) will decrease
      the need for blood transfusions in patients with Acute Lymphocytic Leukemia (ALL),
      Lymphoblastic Lymphoma (LL), or Burkitt's who are receiving chemotherapy. Another goal is to
      study the remission rates in patients with cancer who have received treatment with epoetin
      alfa.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Epoetin alfa is a medication that helps the body make more red blood cells.

      Before treatment you will have a complete physical exam. You will have around 1 tablespoon of
      blood drawn for blood tests (these tests are in addition to the routine blood tests you will
      have as part of your standard of care). Women who are able to have children must have a
      negative blood pregnancy test.

      You will be randomly assigned (as in the toss of a coin) to one of two treatment groups.
      Patients in the first group will be given epoetin alfa once a week at the time chemotherapy
      is started. Patients in the other group will not receive epoetin alfa, but will undergo the
      same laboratory exams and quality of life evaluations as the group of patients who were given
      epoetin alfa.

      Patients in both groups will receive transfusions if their hemoglobin drops below a certain
      level or it the doctor feels it is necessary. These transfusions are considered to be
      standard of care. You will be asked to keep a diary listing the dates of all transfusions you
      receive.

      If you are assigned to receive epoetin alfa, you will be given epoetin alfa once a week
      during your regularly scheduled chemotherapy. You will receive treatment with epoetin alfa
      for up to 6 courses of chemotherapy (usually around 5 months, but may be longer). Epoetin
      alfa will be given to you as an injection under the skin. Once a week, you will have around 1
      tablespoon of blood drawn to check the level of hemoglobin in your blood. If your hemoglobin
      rises above a certain level, treatment with epoetin alfa may be temporarily stopped until
      your hemoglobin level decreases.

      Patients in both groups will continue to receive chemotherapy during this study as scheduled.
      During chemotherapy, you will have around 1 tablespoon of blood drawn every 1-2 weeks for
      routine blood tests (as part of your standard of care for treatment of cancer).

      If you agree to the optional procedures, you will continue receiving epoetin alfa even if
      your hemoglobin levels show that you are not responding to epoetin alfa treatment. However,
      if you do not choose to take part in the optional procedures and you are not responding to
      epoetin alfa treatment, you will be taken off the study.

      If you experience any intolerable side effects that are a result of epoetin alfa or your
      disease gets worse, you will be taken off the study.

      This is an investigational study. Epoetin alfa is FDA approved and commercially available.
      Around 164 patients will take part in this study. All will be enrolled at M. D. Anderson.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2003</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Number of RBC Units Transfused During Initial 5 Months of Treatment</measure>
    <time_frame>5 weeks to 5 Months</time_frame>
    <description>Total number of packed red blood cell (PRBCs) units transfused to participant beginning at fifth week, up until 5-months compared between the evaluable study group subsets.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of PRBC Transfusions During Initial 5 Months of Treatment</measure>
    <time_frame>5 weeks to 5 Months</time_frame>
    <description>Total number of all packed red blood cells (PRBCs) transfusions (events) given to a participant throughout the 6 courses of chemotherapy treatment, collected and reported by participant from fifth week beginning baseline to 5 months.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">109</enrollment>
  <condition>Leukemia</condition>
  <arm_group>
    <arm_group_label>Procrit</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Starting dose 40,000 units subcutaneously once a week with chemotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No Procrit</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No intervention.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Procrit (epoetin alfa)</intervention_name>
    <description>Starting dose 40,000 Units subcutaneously once a week during your regularly scheduled chemotherapy for up to 6 courses of chemotherapy (around 5 months).</description>
    <arm_group_label>Procrit</arm_group_label>
    <other_name>epoetin alfa</other_name>
    <other_name>Epogen</other_name>
    <other_name>Erythropoietin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with a diagnosis of ALL, LL, or Burkitt's receiving induction chemotherapy
             with Hyper-CVAD, any variant of Hyper-CVAD or augmented BFM at MD Anderson Cancer
             Center.

          2. Patients must be enrolled on the study + / - (plus or minus) 14 days from the start of
             induction chemotherapy.

          3. Patients with relapsed ALL, LL, or Burkitt's are eligible, but must have had a
             remission duration of 1 year or longer.

        Exclusion Criteria:

          1. Hemoglobin greater than or equal to 10 g/dL.

          2. Patients with prior treatment with epoetin alfa or any investigational forms of
             erythropoietin within the previous 3 months.

          3. Patients with known hypersensitivity to mammalian-cell derived products or to human
             albumin.

          4. Uncontrolled hypertension

          5. History of thrombotic vascular event.

          6. Pregnant or lactating women.

          7. Anemia due to factors other than cancer, deficiencies of B12, folate, or iron (only
             with concurrent treatment of these deficiencies).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jorge Cortes, MD</last_name>
    <role>Study Chair</role>
    <affiliation>UT MD Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UT MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>UT MD Anderson Cancer Center website</description>
  </link>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 5, 2010</study_first_submitted>
  <study_first_submitted_qc>April 5, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2010</study_first_posted>
  <results_first_submitted>June 12, 2012</results_first_submitted>
  <results_first_submitted_qc>July 24, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 27, 2012</results_first_posted>
  <last_update_submitted>July 24, 2012</last_update_submitted>
  <last_update_submitted_qc>July 24, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 27, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Procrit</keyword>
  <keyword>Acute Lymphocytic Leukemia</keyword>
  <keyword>Lymphoblastic Lymphoma</keyword>
  <keyword>Burkitt's</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Hyper-CVAD</keyword>
  <keyword>augmented BFM</keyword>
  <keyword>Epoetin alfa</keyword>
  <keyword>Epogen</keyword>
  <keyword>Erythropoietin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period 3/11/2003 - 5/25/2011; all patients were registered at The University of Texas M.D. Anderson Cancer Center.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Procrit</title>
          <description>Starting dose 40,000 Units subcutaneously once a week with chemotherapy.</description>
        </group>
        <group group_id="P2">
          <title>No Procrit</title>
          <description>No intervention.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="54"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="54"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Procrit</title>
          <description>Starting dose 40,000 Units subcutaneously once a week with chemotherapy.</description>
        </group>
        <group group_id="B2">
          <title>No Procrit</title>
          <description>No intervention.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="55"/>
            <count group_id="B2" value="54"/>
            <count group_id="B3" value="109"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39" lower_limit="18" upper_limit="76"/>
                    <measurement group_id="B2" value="42" lower_limit="15" upper_limit="84"/>
                    <measurement group_id="B3" value="41" lower_limit="15" upper_limit="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Number of RBC Units Transfused During Initial 5 Months of Treatment</title>
        <description>Total number of packed red blood cell (PRBCs) units transfused to participant beginning at fifth week, up until 5-months compared between the evaluable study group subsets.</description>
        <time_frame>5 weeks to 5 Months</time_frame>
        <population>Transfusion data was available in 79 of the 81 (98%) evaluable patients who completed the treatment/observation period.</population>
        <group_list>
          <group group_id="O1">
            <title>Procrit</title>
            <description>Procrit starting dose 40,000 Units subcutaneously once a week with chemotherapy.</description>
          </group>
          <group group_id="O2">
            <title>No Procrit</title>
            <description>No intervention.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Number of RBC Units Transfused During Initial 5 Months of Treatment</title>
          <description>Total number of packed red blood cell (PRBCs) units transfused to participant beginning at fifth week, up until 5-months compared between the evaluable study group subsets.</description>
          <population>Transfusion data was available in 79 of the 81 (98%) evaluable patients who completed the treatment/observation period.</population>
          <units>PRBC Units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.63" spread="6.29"/>
                    <measurement group_id="O2" value="13.11" spread="5.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of PRBC Transfusions During Initial 5 Months of Treatment</title>
        <description>Total number of all packed red blood cells (PRBCs) transfusions (events) given to a participant throughout the 6 courses of chemotherapy treatment, collected and reported by participant from fifth week beginning baseline to 5 months.</description>
        <time_frame>5 weeks to 5 Months</time_frame>
        <population>Transfusion data was available in 79 of the 81 (98%) evaluable patients who completed the treatment/observation period.</population>
        <group_list>
          <group group_id="O1">
            <title>Procrit</title>
            <description>Starting dose 40,000 Units subcutaneously once a week with chemotherapy.</description>
          </group>
          <group group_id="O2">
            <title>No Procrit</title>
            <description>No intervention.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of PRBC Transfusions During Initial 5 Months of Treatment</title>
          <description>Total number of all packed red blood cells (PRBCs) transfusions (events) given to a participant throughout the 6 courses of chemotherapy treatment, collected and reported by participant from fifth week beginning baseline to 5 months.</description>
          <population>Transfusion data was available in 79 of the 81 (98%) evaluable patients who completed the treatment/observation period.</population>
          <units>transfusions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.22" spread="3.87"/>
                    <measurement group_id="O2" value="7.44" spread="3.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>8 years, 2 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Procrit</title>
          <description>Starting dose 40,000 Units subcutaneously once a week with chemotherapy.</description>
        </group>
        <group group_id="E2">
          <title>No Procrit</title>
          <description>No intervention.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="55"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Seizures</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jorge Cortes M.D./Professor</name_or_title>
      <organization>The University of Texas M. D. Anderson Cancer Center</organization>
      <phone>713/794-5783</phone>
      <email>eharriso@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

